Piramal Enterprises Ltd. share price target

Piramal Enterprises (PIEL) reported 3QFY25 net profit of ~INR386m (PQ: ~INR1.6b). This included exceptional gain of ~INR3.8b (PQ: INR770m) from recoveries in AIF portfolio.

Piramal Enterprises (PIEL) reported a 2QFY25 net profit of ~INR1.6b (PQ: ~INR1.8b). This included an exceptional gain of ~INR770m from recoveries in the AIF portfolio.

PIEL is committed to reducing its legacy AUM from ~INR130b as of Jun’24 to ~INR60-70b by Mar’25 and expects (not guidance) that a ~25% haircut.

PIEL reported 1QFY25 net profit of ~INR1.8b (PQ: ~INR1.4b). This included an exceptional gain of ~INR1b from recoveries in AIF portfolio.

Piramal Enterprises (PEL) reported its first-ever positive quarterly PAT as an NBFC – at Rs35.5bn, well above our estimates. This was its second quarterly result as an NBFC post the demerger of Piramal Pharma. PAT was led by one-offs in terms of: i) income tax provision reversal of Rs33.3bn.

Piramal Enterprises (PEL) once again disappointed, reporting a loss of Rs15bn in Q2FY23, as it provided Rs33bn (>5% of AUM) primarily towards wholesale portfolio.

Piramal Enterprises (PEL) has fixed September 1, ‘22 as demerger of Piramal Pharma record date.

Piramal Enterprises (PIEL) reported a healthy 3QFY22 result, characterized by various factors. a) 44% QoQ growth in retail disbursements exhibited momentum and will continue to improve hereon b) GNPA/NNPA increased just 40bp/30bp QoQ to 3.3%/1.8%, driven by one slippage in the Wholesale segment and the impact of the RBI NPA circular and yet PIEL delivered net provision write-backs. c) The focus was on execution, resulting in steady progress on the articulated strategy and the DHFL integration. d) Ten live fintech and consumer-tech partnerships are evolving well and contributed 96%...

PIEL reported a consolidated PAT of INR4.3b, down 32% YoY and 20% QoQ. This was driven by a decline in Financial Services' (FS) revenue, led by a reduction in the Wholesale loan book. This was also in part because of extra-ordinary expenses of INR1.53b on the DHFL acquisition and the...

PIEL's board approved the simplification of its corporate structure by creating two separate listed entities in Financial and Pharmaceutical Services, subject to shareholder, creditor, and regulatory approvals. The demerger would optimize the capital structure for each business and enable both to independently pursue growth opportunities. We remain positive on PIEL on the back of: a) its fully integrated CDMO presence, b) niche portfolio, with global distribution in the Complex Hospital Generics (CHG) space, c) strong brands with an established pan-India distribution network, d)...